Vectura Group plc: 2017 Preliminary Results - Performance in-line with expectations, with strong in-market growth from key inhaled products
21 mars 2018 08h01 HE
|
VECTURA GROUP PLC
Vectura Group plc 2017 Preliminary Results - Performance in-line with expectations, with strong in-market growth from key inhaled products - Chippenham, UK - 21 March 2018: Vectura Group...
Vectura Group plc: 2017 Pre-close Trading Update and Refocussed Investment Strategy
04 janv. 2018 07h00 HE
|
VECTURA GROUP PLC
This announcement contains inside information Vectura Group plc 2017 Pre-close Trading Update and Refocussed Investment Strategy Chippenham, UK - 4 January 2018: Vectura Group plc (LSE:...
Vectura Group plc: New development and licence agreement for a US inhaled generic (VR2081)
28 juin 2017 12h22 HE
|
VECTURA GROUP PLC
Vectura Group plc New development and licence agreement for a US inhaled generic (VR2081) Chippenham, UK - 28 June 2017: Vectura Group plc (LSE: VEC) ("Vectura", "the Group"), an...
Vectura Group plc: Launch of UtibronTM Neohaler® in the US
03 avr. 2017 08h38 HE
|
VECTURA GROUP PLC
Vectura Group plc Launch of UtibronTM Neohaler® in the US Chippenham, UK - 3 April 2017: Vectura Group plc (LSE: VEC) ("Vectura", "the Group"), an industry-leading device and...
Vectura Group plc: Pre-close update
11 janv. 2017 07h04 HE
|
VECTURA GROUP PLC
Vectura Group plc Pre-close update Significant business development progress with year-end revenues in line with expectations Chippenham, UK - 11 January 2017: Vectura Group plc (LSE: VEC)...
Vectura Group plc: Licensing agreement signed for the launch of Utibron/Seebri in the US
21 déc. 2016 17h19 HE
|
VECTURA GROUP PLC
Vectura Group plc (LSE:VEC) ("Vectura", "the Group"), an industry-leading inhaled airways disease focused business, reports that Novartis announced today that it has signed a licensing agreement with...